Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

594.32 +9.33 (+1.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
49 50 Next >
Wall Street Has High Hopes for These 2 Nasdaq Stocks
Even in choppy markets, there are smart investments you can make. 
Via The Motley Fool
Stock Market Split As Fed Hikes Rates, Banks Keep Tumbling; Nvidia, On Holding In Focus: Weekly Review
The major indexes showed volatile, divergent action. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2023
Via Benzinga
Regeneron Pharmaceuticals Analysts React To Drug Trial Results: Why Whales Are Diving In
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced the Phase 3 trial of Dupixent (dupilumab), developed with Sanofi (NASDAQ: SNY), for uncontrolled chronic obstructive pulmonary disease (COPD) met... 
Via Benzinga
Regeneron Pharmaceuticals (NASDAQ: REGN) is a Leading Gainer in 3/23 Morning Trading
Via Investor Brand Network
Why Shares of Regeneron Are Rising Thursday
Regeneron released positive phase 3 trial results for its therapy Dupixent. 
Via The Motley Fool
Regeneron Pharmaceuticals Options Traders Betting On Stock Falling This Much By April Expiration
Sanofi (NASDAQ: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares surged on Thursday after the companies announced primary and all key secondary endpoints were met in a Phase 3 trial... 
Via Benzinga
US Stocks On Track For Weak Start Friday Amid Renewed Banking Concerns And Contagion Fears
Renewed concerns about the banking system appear to weigh on stocks, as the major index futures point to a sharply lower opening on Friday. 
Via Benzinga
Why Are Stocks Up Today?
Stocks are up today as investors react to the latest news from the Federal Reverse concerning a new interest rate increase. 
Via InvestorPlace
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
Via Benzinga
REGN Stock Alert: Regeneron Pharmaceuticals Gains on Dupixent Drug Data
Regeneron Pharmaceuticals (REGN) stock is on the rise Thursday after the company released its latest clinical trial data on Dupixent. 
Via InvestorPlace
This Is What Whales Are Betting On Regeneron Pharmaceuticals
Via Benzinga
Regeneron, Sanofi Soar On Blow-Out Results In 'Smoker's Lung'
The companies' Dupixent reduced exacerbations by 30%. 
Via Investor's Business Daily
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,200 Today
Via Benzinga
Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity
Via Benzinga
Apple Jumps Movie Production Bandwagon, Billionaire Jim Ratcliffe Bids For Manchester United, Elon Musk Seeks Funding For SpaceX From Middle-Eastern Fund: Today's Top Stories
Bloomberg 
Via Benzinga
Why Regeneron Pharmaceuticals And Sanofi Shares Are Trading Higher Today
Sanofi-Regeneron stocks are trading higher today after their blockbuster drug aced the pivotal COPD trial. 
Via Benzinga
Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
7 Value Stocks Worth Buying at These 52-Week Highs
While these value stocks to buy are trading near their 52-week highs, they still have plenty of gas left in the tank for investors. 
Via InvestorPlace
Where Regeneron Pharmaceuticals Stands With Analysts
Via Benzinga
How Is The Market Feeling About Regeneron Pharmaceuticals?
Via Benzinga
FDA Approves First-in-class Evkeeza® (evinacumab-dgnb) for Young Children with Ultra-rare Form of High Cholesterol
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Week In Review: Livzon In-Licenses GERD Therapy In $127 Million Agreement
Livzon Pharmaceutical Group entered a $127.5 million agreement for China rights to a gastroesophageal reflux disease therapy from Onconic Therapeutics. Meanwhile, Gracell Biotech announced that it had... 
Via Talk Markets
Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Medicare Negotiation Hammers Biotech Stocks Regeneron, Halozyme
It's still unclear whether CMS will include those drugs in its negotiation list. 
Via Investor's Business Daily
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease
$250,000 top award goes to Neel Moudgal in the nation’s oldest and most prestigious science and math competition for high school seniors 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
2 Biotech Stocks You Can Buy and Hold for the Next Decade
Regeneron and Sarepta Therapeutics have been on fire so far this year. 
Via The Motley Fool
Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review
More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistamines 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
49 50 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.